1 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
|
2 |
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
|
3 |
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203.
|
4 |
Clinical pipeline report, company report or official report of Nektar Therapeutics.
|
5 |
Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
|
6 |
Clinical pipeline report, company report or official report of CureVac.
|
7 |
Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech.
|
8 |
Clinical pipeline report, company report or official report of GlaxoSmithKline
|
9 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
10 |
Clinical pipeline report, company report or official report of Silverback Therapeutics.
|
11 |
VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6.
|
12 |
Clinical pipeline report, company report or official report of Array BioPharma (Drug: Motolimod / VTX2337).
|
13 |
Clinical pipeline report, company report or official report of Idera Pharmaceuticals.
|
14 |
Oligodeoxynucleotide inhibition of Toll-like receptors 3, 7, 8, and 9 suppresses cytokine production in a human rheumatoid arthritis model. Eur J Immunol. 2016 Mar;46(3):772-81.
|
15 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1758).
|
|
|
|
|
|
|